MAY 24, 2018 12:48 AM PDT

The Link Between Tuberculosis and Parkinson Disease

WRITTEN BY: Nouran Amin

There might be a link between Tuberculosis (TB) and Parkinson’s according to a study published in The EMBO Journal. This link is related to the mechanism behind how our immune system eradicates bacterial infections. More specifically, the study concluded that the mechanism is the same for Tuberculosis and Parkinson.

The findings, which will be published in The EMBO Journal, provide a possible explanation of the cause of Parkinson's disease and suggest that drugs designed to treat Parkinson's might work for TB too.

For Parkinson's disease, the most common genetic mutation occurs on the LRRK2, which allows the LRRK2 protein overactive. By examining the function of LRRK2 in immune cells known as macrophages that are infected with Mycobacterium tuberculosis (Mtb), the bacterium that leads to TB.

Using a combination of experimental approaches, Crick and GSK researchers, in collaboration with Matthias Trost, a proteomics specialist, from Newcastle University, discovered that LRRK2 inhibits phagosomes from fusing with lysosomes, decreasing their efficacy at clearing bacteria. Deletion of the LRRK2 gene or cell treatment using LRRK2 blockers might significantly reduce the levels of Mtb, treating TB. "We think that this mechanism might also be at play in Parkinson's disease, where abnormal masses of protein called 'Lewy bodies' build up in neurons in the brain and cause damage," explains Susanne Herbst, the first author of the study and post-doctoral fellow at the Crick.

Investigators suspect that LRRK2 might inhibit immune cells in the brain from degrading causing a build-up of protein in neurons that disrupts their neuronal function. "By studying TB, we have found a possible explanation for why LRRK2 mutations are a genetic risk factor for Parkinson's disease. It's exciting when different fields of research connect up in unexpected ways like this!" notes Susanne.

The findings also suggest that LRRK2 inhibitors could be a powerful new way for TB treatment. "LRRK2 inhibiting drugs are already being developed to treat Parkinson's disease and we're trying to see if we can repurpose them as a potential new TB therapy. This should be relatively straightforward because TB infects the lungs, so the LRRK2 inhibitors wouldn't need to cross the blood-brain barrier like they do in Parkinson's disease."

Sources: Crick

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 26, 2020
Microbiology
Researchers Design A Polio Vaccine That Won't Cause Polio
APR 26, 2020
Researchers Design A Polio Vaccine That Won't Cause Polio
Sustained, intense efforts to vaccinate were getting the world very close to eradicating polio, but the vaccine itself o ...
MAY 17, 2020
Coronavirus
Substantial Antiviral Response Seen in Adults Recovered from COVID-19
MAY 17, 2020
Substantial Antiviral Response Seen in Adults Recovered from COVID-19
Some good news comes as researchers scramble for potential vaccine candidates amidst the global COVID-19 pandemic. Scien ...
JUN 04, 2020
Clinical & Molecular DX
Low T Cells Linked To High COVID Risk
JUN 04, 2020
Low T Cells Linked To High COVID Risk
  German scientists have found a link between immune cell counts and the risk of developing severe, potentially lif ...
JUN 15, 2020
Drug Discovery & Development
FDA Approves HPV Vaccine to Prevent Throat Cancer
JUN 15, 2020
FDA Approves HPV Vaccine to Prevent Throat Cancer
For around a decade, research has suggested that Gardasil, an HPV vaccine, could prevent throat cancer, a condition that ...
JUL 15, 2020
Immunology
Immune Memory to Thwart Recurring Cancer
JUL 15, 2020
Immune Memory to Thwart Recurring Cancer
Preventing cancer from returning in the body is an integral part of any anti-cancer treatment plan. New discoveries from ...
JUL 29, 2020
Drug Discovery & Development
Will We Have a COVID-19 Vaccine by Year-End?
JUL 29, 2020
Will We Have a COVID-19 Vaccine by Year-End?
This week, pharmaceutical companies Moderna and Pfizer launched giant Phase III 30,000-subject trials for their COVID-19 ...
Loading Comments...